(New York, NY) – June 7th, 2013 – Ai Cure Technologies, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, today announced it was awarded a highly competitive National Institutes of Health (NIH) innovation grant in the amount of $1.8 million by the National Center For Advancing Translational Sciences. According to the NIH grant summary report, Ai Cure’s technology will have “a significant impact… [and] widespread application in research and in care.”
Ai Cure’s platform, AiView®, automates the process of directly observed therapy (DOT), confirming that a patient has ingested their medication, instead of relying on derivative measures such as pill counts, electronic pill bottles or other methods that imply but do not confirm medication is taken. AiView® was developed as a software solution to maximize flexibility, minimize cost, and ensure complete accuracy.
The grant will fund the second phase of a research study involving two distinct patient populations to demonstrate the efficacy and validity of Ai Cure’s computer vision technology platform to accurately monitor and intervene in patient medication adherence. The digital health solution works in real time and leverages mobile platforms to visually confirm whether a patient has correctly taken their medication. Data from each dosing is automatically stored and provides a continuous and uninterrupted audit trail of patient adherence over time, leading to precise individual adherence trends and predictive algorithms to facilitate tailored intervention.
The two randomized controlled clinical trials will compare adherence rates between patients assigned to use the Ai Cure Technologies platform and those monitored as per usual (pill count). The studies are being performed in collaboration with two teaching hospitals and will focus on patients being treated for depression and stroke, two populations representing a wide range of ages and demographics and both at high risk of non-adherence.
Laura Shafner, Senior Director of Healthcare Research and Strategy at Ai Cure Technologies said, “We are grateful for this latest funding and honored that the NIH sees the potential for Ai Cure to positively affect clinical research and patient care. Our goal is to set a gold standard – where none currently exists – for how medication adherence is tracked and managed.”
The trials will be taking place at North Shore-LIJ Health System / Zucker Hillside Hospital and at the Albert Einstein College of Medicine / Montefiore Medical Center.